Patent ID: 8263599

Claim:
A method for inhibiting STAT3 activation in a patient having a symptom or disease selected from autoimmune disease, diabetes, infection, Alzheimer's disease, psoriasis, but not fibrosis, comprising administering, to said patient, an effective amount of a compound selected from the group consisting of: (1) N-[6-(4-{[2-(4-piperonylpiperazin-1-yl)-2-oxoethyl]ethylaminol}-2-methoxyphenoxy)pyridin-3-yl]-3,4-dichlorobenzamide, (2) N-{2[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2-oxoethyl}-N-{4-[(5-{methyl[4-(trifluoromethyl)benzyl]amino}pyridin-2-yl)oxy]phenyl}acetamide (3) N-(6-{4-[3-(4-piperonylpiperazin-1-yl)-3-oxopropyl]phenoxy}pyridin-3-yl)-4-trifluoromethylbenzamide, (4) N-[4-(4-{[2-(4-piperonylpiperazin-1-yl)-2-oxoethyl]methylamino}phenoxy)phenyl]-4-trifluoromethylbenzamide, (5) N-[6-(4-{[2-(4-piperonylpiperazin-1-yl)-2-oxoethyl]ethylamino}-2-methoxyphenoxy)pyridin-3-yl]-4-trifluoromethylbenzamide, (6) N-[6-(4-{[2-(4-piperonylpiperazin-1-yl)-2-oxoethyl]methylamino}-2-methylphenoxy)pyridin-3-yl]-4-trifluoromethylbenzamide, and (7) N-[6-(4-{[(4-pivaloylbenzyl)piperazin-1-yl]oxomethyl}phenoxy)pyridin-3-yl]-3,4-dichlorobenzamide, or a salt thereof.